Dyne Therapeutics updates year-end cash at $1.1B

Dyne Therapeutics, Inc. reported that it expects to disclose cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. reported that it expects to disclose cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025. The company noted that its fourth-quarter and full-year 2025 financial results are not yet finalized and this cash figure is a preliminary, unaudited management estimate that remains subject to completion of normal closing procedures.

The company also made available an investor presentation on January 12, 2026, covering its current operations, future plans and other business updates. The presentation was filed as Exhibit 99.1 and is incorporated by reference, while the cash update and presentation are furnished for information purposes and are not deemed filed under securities laws unless specifically incorporated in other documents.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What cash balance does Dyne Therapeutics (DYN) expect to report for year-end 2025?

Dyne Therapeutics expects to report approximately $1.1 billion in cash, cash equivalents and marketable securities as of December 31, 2025.

Are Dyne Therapeutics' reported cash figures for December 31, 2025 final?

No. The $1.1 billion cash, cash equivalents and marketable securities figure is described as preliminary and unaudited and remains subject to completion of financial closing procedures.

Has Dyne Therapeutics' auditor reviewed the preliminary $1.1 billion cash estimate?

The company states that its independent registered public accounting firm has not conducted an audit or review of the estimated cash figure and does not express any opinion or assurance on it.

What did Dyne Therapeutics file under Item 7.01 of this 8-K?

Dyne Therapeutics furnished an investor presentation dated January 12, 2026 as Exhibit 99.1, covering current operations, future plans and other business updates.

Are the cash update and investor presentation considered filed for liability purposes?

The company specifies that information under Item 2.02 and Item 7.01, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act, unless later incorporated by reference.

What is the main focus of this Dyne Therapeutics 8-K filing?

The filing primarily provides a preliminary year-end 2025 cash, cash equivalents and marketable securities estimate of about $1.1 billion and furnishes an investor presentation with operational and strategic updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 07:35 AM Learn about SEC filing dates

0001818794false00018187942026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 12, 2026

Dyne Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-39509	36-4883909
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1560 Trapelo Road Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 786-8230

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value per share		DYN		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Dyne Therapeutics, Inc. (the “Company”) disclosed on January 12, 2026, that although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, it expects to report cash, cash equivalents and marketable securities of approximately $1.1 billion as of December 31, 2025.

The estimated cash figure is preliminary and unaudited, represents a management estimate as of the date of this Current Report on Form 8-K and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated cash figure.

The information furnished under this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, the Company made available a presentation to be used with investors to discuss the Company's current operations, future plans and other business updates. A copy of the presentation is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Presentation, dated January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		DYNE THERAPEUTICS, INC.
Date: January 12, 2026		By:		/s/ John G. Cox
				Name:		John G. Cox
				Title:		President and Chief Executive Officer